Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...

Genentech, part of the Roche (ROG SIX) group, has received a new approval from the US Food and Drug Administration for TNKase ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

Genentech and Novartis have teamed up with Food Allergy Research & Education (FARE) to enhance the safety of children with ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...